Bright Minds Biosciences

Update in progress

DRUG (NasdaqCM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Bright Minds Biosciences is a New York–based biotechnology company developing therapeutics for severe neurological and neuropsychiatric diseases. Its portfolio centers on 5-HT2 receptor programs and BMB-101, which has completed a Phase 1 trial and is in Phase 2 for developmental and epileptic encephalopathies and absence seizures. It also develops BMB-201, BMB-202, and BMB-105, a 5-HT2C agonist for Prader-Willi syndrome. The company collaborates with Firefly Neuroscience to analyze EEG data in its BREAKTHROUGH study. Founded 2017.

Company score

Sentiment: 0.34; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.22; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.12; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.09; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.21; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive